Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EA5 in Anti-AChR Positive Generalized Myasthenia Gravis
NCT07818291Phase 1Not yet recruiting
- Sponsor
- Lan-Yi Therapeutics
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of EA5 in myasthenia gravis (MG) (3 arms), sponsored by Lan-Yi Therapeutics. Primary endpoint: Incidence and Severity of Treatment Emergent Adverse Events. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
EA5
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07818291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07818291.